Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells

Abstract

Compositions and preparations of fetal support tissue that prevent or reduce the proliferation and epithelial-mesenchymal transition (EMT) of epithelial cells, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or reducing the proliferation, cell migration, and EMT of epithelial cells in an individual in need thereof, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or treating proliferative vitreoretinopathy in an individual in need thereof.

What is claimed is: 
     
         1 . An composition for preventing or reducing proliferation, cell migration, or epithelial-mesenchymal transition (EMT) of epithelial cells, comprising:
 (a) a preparation of fetal support tissue; and   (b) a pharmaceutically acceptable diluent, excipient, vehicle, or carrier.   
     
     
         2 . The composition according to  claim 1 , wherein the fetal support tissue is selected from placenta, placental amniotic membrane, umbilical cord, umbilical cord amniotic membrane, chorion, amnion-chorion, amniotic stroma, amniotic jelly, or a combination thereof. 
     
     
         3 . The composition of  claim 1 , wherein the fetal support tissue is frozen or previously frozen. 
     
     
         4 . The composition according to  claim 1 , wherein the epithelial cells are selected from retinal pigment epithelial cells (RPE), conjunctival epithelial cells, corneal epithelial cells, limbal epithelial cells, and renal epithelial cells. 
     
     
         5 . The composition according to  claim 1 , wherein the epithelial cells are human epithelial cells. 
     
     
         6 . The composition of  claim 1 , wherein the preparation of fetal support tissue is an extract of fetal support tissue, a homogenate, a powder, morselized fetal support tissue, pulverized fetal support tissue, ground fetal support tissue, purified HC-HA/PTX3, or a combination thereof. 
     
     
         7 . The composition according to  claim 1 , wherein the composition is a gel, a solution, or a suspension. 
     
     
         8 . The composition according to  claim 1 , wherein the preparation comprises HC-HA/PTX3. 
     
     
         9 . The composition according to  claim 1 , wherein the composition is for local administration. 
     
     
         10 . The composition according to  claim 1 , wherein the composition is formulated for intraocular injection, subretinal injection, intravitreal injection, periocular injection, subconjunctival injection, retrobulbar injection, intracameral injection, or sub-Tenon's injection. 
     
     
         11 . An injectable composition for treating or preventing Proliferative Vitreoretinopathy (PVR) consisting essentially of:
 (a) substantially isolated HC-HA/PTX3, reconstituted HC-HA/PTX3, or a combination thereof; and   (b) a pharmaceutically acceptable diluent, excipient, vehicle, or carrier;   wherein the composition is suitable for injection.   
     
     
         12 . The composition according to  claim 11 , wherein the HC-HA/PTX3 is isolated from a fetal support tissue, wherein the fetal support tissue is placenta, placental amniotic membrane, umbilical cord, umbilical cord amniotic membrane, chorion, amnion-chorion, amniotic stroma, amniotic jelly, or a combination thereof. 
     
     
         13 . The composition of  claim 12 , wherein the fetal support tissue is frozen or previously frozen. 
     
     
         14 . The composition of  claim 11 , wherein the composition is in an amount effective for preventing or reducing the proliferation, cell migration or EMT of epithelial cells. 
     
     
         15 . The composition of  claim 14 , wherein the epithelial cells are retinal pigment epithelial cells (RPE). 
     
     
         16 . The composition of  claim 14 , wherein the epithelial cells are human epithelial cells. 
     
     
         17 . The composition of  claim 11 , wherein the substantially isolated HC-HA/PTX3 is isolated from fetal support tissue by ultracentrifugation. 
     
     
         18 . The composition according to  claim 11 , wherein the composition is a gel, a solution, or a suspension. 
     
     
         19 . The composition according to  claim 11 , wherein the composition is formulated for intraocular injection, subretinal injection, intravitreal injection, periocular injection, subconjunctival injection, retrobulbar injection, intracameral injection or sub-Tenon's injection. 
     
     
         20 . An injectable composition for treating or preventing Proliferative Vitreoretinopathy (PVR) consisting essentially of:
 (a) substantially isolated HC-HA/PTX3, reconstituted HC-HA/PTX3, or a combination thereof;   (b) an additional therapeutic agent; and   (c) a pharmaceutically acceptable diluent, excipient, vehicle, or carrier;   
       wherein the composition is suitable for injection. 
     
     
         21 . An injectable composition for treating or preventing Proliferative Vitreoretinopathy (PVR) comprising:
 (a) a preparation of fetal support tissue comprising HC-HA/PTX3 and at least one other component of fetal support tissue; and   (b) a pharmaceutically acceptable diluent, excipient, vehicle, or carrier;   
       wherein the composition is suitable for injection. 
     
     
         22 . The composition according to  claim 21 , wherein the fetal support tissue is placenta, placental amniotic membrane, umbilical cord, umbilical cord amniotic membrane, chorion, amnion-chorion, amniotic stroma, amniotic jelly, amniotic fluid, or a combination thereof. 
     
     
         23 . The composition of  claim 21 , wherein the fetal support tissue is frozen or previously frozen. 
     
     
         24 . The composition of  claim 21 , wherein the composition is in an amount effective for preventing or reducing the proliferation, cell migration or EMT of epithelial cells. 
     
     
         25 . The composition according to  claim 24 , wherein the epithelial cells are retinal pigment epithelial (RPE) cells. 
     
     
         26 . The composition of  claim 21 , wherein the preparation of fetal support tissue is an extract of fetal support tissue, micronized fetal support tissue, a homogenate, a powder, morselized fetal support tissue, pulverized fetal support tissue, ground fetal support tissue, purified HC-HA/PTX3, or a combination thereof. 
     
     
         27 . The composition according to  claim 21 , wherein the composition is a gel, a solution, or a suspension. 
     
     
         28 . The composition according to  claim 21 , wherein the fetal support tissue is human, non-human primate, bovine, or porcine. 
     
     
         29 . The composition according to  claim 21 , wherein the composition is formulated for intraocular injection, subretinal injection, intravitreal injection, periocular injection, subconjunctival injection, retrobulbar injection, intracameral injection or sub-Tenon's injection.